This is the 3rd Annual meeting of the PReDiCTR Consortium, a UM1 cooperative agreement between the University of California San Francisco and DMID/NIAID. entitled "Preclinical Design and Clinical Translation of TB Regimens.
This project has established a comprehensive, collaborative, multidisciplinary consortium of scientific leaders, drug developers and other stakeholders to
develop and pursue a preclinical and translational research agenda to identify novel regimens with the greatest potential for clinical success in adults and children with TB. The overarching hypothesis is that integration and analysis of specific preclinical and early clinical data using validated models and tools will enable data-driven clinical trial simulations that yield quantitative predictions of Phase 2 and Phase 3 trial endpoints useful to identify and rank regimens with the highest probability of clinical success in patients across the age and disease spectrum of pulmonary TB.
By generating adequate and comparable preclinical data on regimen efficacy, pharmacometrics, toxicities, drug-drug interactions, and other factors essential for human clinical trials, the consortium will increase efficiency, accelerate development of new combinations, and identify the most promising regimens for future clinical testing to effect shorter, relapse-free cures of pulmonary TB in adults, children, and persons being treated for HIV.
